Brødkrumme Forside Enliven Therapeutics Enliven Therapeutics Enliven Therapeutics is developing a novel, chronic, oral treatment for patients with sickle cell disease and other haemoglobinopathies. Related news about Enliven Therapeutics Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease IMARA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING Imara Announces Presentation at the Annual Sickle Cell and Thalassaemia Conference Imara Announces Upcoming Presentation at the 46th Annual National Sickle Cell Disease Association of America (SCDAA) Convention Imara Announces CEO Rahul Ballal, Ph.D., Will Present at the 7th Annual Sickle Cell Disease Therapeutic Conference Enliven Therapeutics' website Lundbeckfonden BioCapital Investeringsår 2016 IPO in 2020 – ENVL (Nasdaq) Lokation Boston, Massachusetts, USA
